Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Recently, the availability of R has substantially changed therapeutic approach to FL
patients, since its combination with chemotherapy has improved response rates, progression
free survival (PFS) and overall survival (OS). Based on the results of recently completed
randomized studies the standard treatment for patients with FL should consist of an initial
therapy with R-CHOP combination followed by two-year maintenance with R. Although results of
randomized trials confirmed that this approach results in an improved patients' outcome and
made a step forward in the management of patients with FL, one important question that can be
raised is if this approach is really needed for all patients with FL or if some of them could
benefit from a reduced intensity treatment achieving the same results in terms of outcome and
survival . This question is of particular interest for newly diagnosed patients for whom
maintenance does not affect OS.
More recent data demonstrated that the outcome of patients with FL can be further predicted
by evaluating the quality of response to therapy studying minimal residual disease (MRD).
This project addresses the objective of evaluating if combining clinical response assessed on
FDG-PET scan and molecular response measured through MRD detection could permit to single out
groups of patients at different risk of progression and to consequently modulate maintenance
therapies, with the aim to provide clinicians a more rational use of the available diagnostic
and therapeutic resources.